Medicine recalls
|
| |
| Singapore: Voluntary batch recall for Taxotere Concentrate for solution for infusion 20 mg/ml and 80 mg/4ml |
| |
Sanofi-Aventis Singapore Pte. Ltd. has issued a Dear Healthcare Professional Letter to inform healthcare professionals of a voluntary recall for selected batches of Taxotere Concentrate for solution for infusion 20 mg/ml (SIN14106P) and Taxotere Concentrate for solution for infusion 80 mg/4ml (SIN14107P).
A failure in the filling process has led to a low number of potentially over-concentrated Taxotere Concentrate vials. As a precautionary measure, Sanofi has initiated the voluntary recall of these affected batches.
As a consequence, a risk of shortage is anticipated in Singapore. Healthcare providers should carefully monitor patients for signs of toxicity and treat appropriately. In case of a shortage, patients previously treated with Taxotere should preferably be switched to an alternative.
Please refer to the following website in HSA for details:
http://www.hsa.gov.sg/content/hsa/../voluntary-batch-recallfortaxotereconcentrateforsolutionforinfusi.html
In Hong Kong, Taxotere Concentrate for Solution for Infusion 20mg/ml (HK-60551) and Taxotere Concentrate for Solution for Infusion 80mg/4ml (HK-60552) are pharmaceutical product registered by Sanofi-Aventis Hong Kong Limited (Sanofi), and are prescription only medicines. Related news was previously issued by the MHRA, and was posted on the Drug Office website on 21 April 2016. As confirmed with Sanofi, the affected batches have not been imported into Hong Kong for local distribution.
Ends/ Friday, April 29, 2016
Issued at HKT 15:30
|
| |
|
